Evidence map›Paper›PMID 36337064›Full record

ArticleIranian journal of biotechnology2022

Epigenteic Alteration of

Arash Moradi, Seyed Ahmad Aleyasin, Kamal Mohammadian, Aida Alizamir

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Arash MoradiDepartment of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Seyed Ahmad AleyasinDepartment of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Kamal MohammadianDepartment of Radiation Oncology, Hamadan University of Medical Sciences, Mahdieh center, Hamadan, Iran.
Aida AlizamirDepartment of Pathology, Hamadan University of Medical Sciences, Hamadan, Iran.
National Institute of Genetic Engineering and Biotechnology · IRHamedan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Intestinal metaplasia (IM) is a benign lesion with no serious concern for patients' health. On the other hand, gastric cancer (GC) is a malignant lesion that has to be differentially diagnosed from benign intestinal metaplasia. Epigenetic modifications have been suggested to play an important role in cancer initiation and development, and they have been investigated as a reliable biomarker tool even for early cancer diagnosis. Whole blood leucocytes (WBC) are potentially the most accessible tissue for cancer early diagnosis, especially for GC, which is hard to diagnose in the early stage. Objective: This study aims to investigate the methylation status of Material and Method: DNA was extracted from the whole blood of 30 IM patients, 30 GC patients, and 34 normal controls samples, and MSRE-PCR was utilized to evaluate the loci methylation status. Results: Significant hypermethylation of Conclusions: This is the first reported on hypermethylation in

Indexed as

DOK7EpigeneticMethylationMSREMSRE-PCR

Identifiers

PMID36337064
PMCPMC9583823
OpenAlexW4308549147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.